SEGMENT REPORTING

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE H - SEGMENT REPORTING

We are a medical device company serving the surgical product and cancer treatment markets, operating in two business segments. Our surgical products business consists of wound closure, vascular access, and specialty needle products.  Our brachytherapy seed business manufactures, custom loads, markets, and distributes “seeds” used primarily in the minimally invasive treatment of localized prostate cancer.  Our brachytherapy product line includes our palladium-103 TheraSeed® device and our iodine-125 AgX100® device.

The following tables provide certain information for these segments (in thousands):

	Quarter Ended March 31,
	2013			2012
Revenues
Surgical products	$	14,483		$	15,494
Brachytherapy seed		5,719			6,320
Intersegment eliminations		(329	)		(231	)
	$	19,873		$	21,583
Earnings (loss) from operations
Surgical products	$	(335	)	$	199
Brachytherapy seed		399			1,380
Intersegment eliminations		(47	)		(3	)
	$	17		$	1,576
Capital expenditures
Surgical products	$	412		$	272
Brachytherapy seed		115			57
	$	527		$	329
Depreciation and amortization
Surgical products	$	1,236		$	1,229
Brachytherapy seed		768			754
	$	2,004		$	1,983

We evaluate business segment performance based on segment revenue and segment earnings (loss) from operations.Earnings (loss) from operations by segment do not include interest expense, interest income, other income and expense, or provisions for income taxes.  Intersegment eliminations are for surgical products segment sales transactions.  Corporate expenses are allocated based upon the relative revenue for each segment.

Supplemental information related to significant assets follows (in thousands):

	March 31, 2013			December 31, 2012
Identifiable assets
Surgical products	$	69,965		$	70,361
Brachytherapy seed		61,577			62,474
Corporate investment in subsidiaries		111,439			111,439
Intersegment eliminations		(137,854	)		(138,549	)
	$	105,127		$	105,725
Intangible assets
Surgical products	$	5,958		$	6,644
Brachytherapy seed		4,167			4,376
	$	10,125		$	11,020

Information regarding revenue by geographic regions follows (in thousands):

	Quarter Ended March 31,
	2013		2012
Product sales
United States	$	16,012	$	18,948
Europe		2,203		1,509
Other foreign countries		997		522
		19,212		20,979
License and fee income
United States		268		247
Canada		393		357
		661		604
	$	19,873	$	21,583

Foreign sales are attributed to countries based on the location of the customer. Thelicense fees attributed to Canada are with Nordion, a Canadian based company, for the license of our TheraSphere® product.  Less than 10% of all foreign product sales are related to the brachytherapy segment.  Substantially all of our long-lived assets are located within the United States.